IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

IDEAYA reported updated clinical data supporting darovasertib plus crizotinib across metastatic uveal melanoma groups: in OptimUM-01, treatment-naïve patients had median PFS of 7.4 months and median overall survival of 27.1 months; the overall cohort’s median PFS was 5.4 months. In OptimUM-02, first-line median PFS was 6.9 months by blinded independent review versus 3.1 months with investigator’s choice, while OptimUM-09 reported a 57% eye-preservation rate and reduced planned radiation dose to critical eye structures for 66% of plaque-brachytherapy patients. Darovasertib remains investigational; IDEAYA expects to complete its combination NDA submission in the second half of 2026.

Analysis

The commercial upside is not simply a larger eligible population: activity in HLA-A*02:01-negative disease could reduce dependence on biomarker-based treatment segmentation and simplify first-line positioning. But the evidence is uneven across segments. The randomized OptimUM-02 comparison is the strongest basis for a near-term label; OptimUM-01’s small treatment-naïve and post-tebentafusp subsets are hypothesis-generating, not proof that the combination displaces tebentafusp across HLA-positive patients. The historical-control comparisons in the release should not be treated as a substitute for randomized evidence.

The primary-disease opportunity is a separate, longer-duration option, not yet a revenue catalyst on par with metastatic approval. Eye preservation and radiation reduction could alter local-treatment decisions, but durable vision, local control, and metastasis outcomes—not shrinkage alone—will determine adoption. Any shift toward organ preservation also requires ophthalmic-oncology workflow changes; a Phase 2 signal does not establish those outcomes.

Near term, ESMO may produce a volatility event, but much of the metastatic signal and OptimUM-09 story is already disclosed. The higher-value catalysts are completion of the NDA submission in H2 2026 and FDA review. Main downside: regulatory requests for additional evidence, weaker-than-expected full trial detail, or tolerability limiting sustained dosing. The contrarian risk is that investors extrapolate historical-benchmark comparisons and early eye-preservation data into broad commercial success before durability and regulatory scope are clear.

Key Decisions for Investors

• Do not chase IDYA solely on the release. Treat the Oct. 24 ESMO presentations as a diligence catalyst: verify patient-level subgroup denominators, follow-up, response durability, dose intensity, and adverse-event discontinuations before increasing exposure.
• For event-driven exposure, consider only a small, defined-risk IDYA call spread around ESMO, and only if option pricing is reasonable relative to implied volatility; spot price, valuation, and options data are absent, so this is a setup to price—not a recommendation to transact now.
• Track the H2 2026 NDA submission and subsequent FDA questions as the 1–3 month/near-term thesis test. Falsification: a submission delay, a narrower-than-expected filing population, or regulatory requests that undermine the anticipated first-line path.
• Keep OptimUM-09 as a 6–18 month option rather than underwriting it in the base case. Upgrade only with evidence of durable eye preservation, maintained vision, and local control; shrinkage without those endpoints would weaken the primary-disease thesis.